Moreover, mutations which are commonly mutated in MDS, including SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR and STAG2, have been specifically linked to secondary AML as opposed to de novo AML patients, suggesting that they may primarily drive the specific biology of the disease [9]. This evidence concerns the gene ZRSR2 and acute myeloid leukemia.